

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0551-0091
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)


Sheet 1 of 31

Complete if Known

| | |
|------------------------|-----------------|
| Application Number | 10/823,463 |
| Filing Date | April 12, 2004 |
| First Named Inventor | Schenk, D. B. |
| Art Unit | 1847 |
| Examiner Name | Nichols, C. J. |
| Attorney Docket Number | 15270J-004754US |

U.S. PATENT DOCUMENTS

| Examiner | Chg No. ¹ | Document Number Number (Kind Code ² (if known)) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Column, Lines, Where Relevant Passages or Relevant Figures Appear |
|----------|----------------------|---|--------------------------------|--|--|
| CW | 578 | 6,875,434 | 04-05-2005 | Schenk | |
| | 877 | 6,866,849 | 03-15-2005 | Schenk | |
| | 575 | 6,868,850 | 03-15-2005 | Schenk | |
| | 576 | 6,818,218 | 11-16-2004 | Schenk | |
| | 563 | 6,787,637 | 09-07-2004 | Schenk et al. | |
| | 572 | 6,761,888 | 07-13-2004 | Schenk | |
| | 562 | 6,750,324 | 08-15-2004 | Schenk et al. | |
| | 573 | 6,743,427 | 06-01-2004 | Schenk | |
| | 442 | 6,713,450 B2 | 03-30-2004 | Frangione et al. | |
| | 444 | 2004/0043418 A1 | 03-04-2004 | Holtzman et al. | |
| | 415 | 2003/0166558 A1 | 09-04-2003 | Frangione et al. | |
| | 431 | 2003/0165498 A1 | 09-04-2003 | Basi et al. | |
| | 544 | 2003/0147882 A1 | 08-07-2003 | Solomon et al. | |
| | 432 | 6,562,341 B2 | 05-13-2003 | Prusiner et al. | |
| | 360 | 2003/0073655 A1 | 04-17-2003 | Chain | |
| | 370 | 2003/0068325 A1 | 04-10-2003 | Wang | |
| | 378 | 2002/0197258 A1 | 12-26-2002 | Ghanbari et al. | |
| | 368 | 2002/0187157 A1 | 12-12-2002 | Jensen et al. | |
| | 377 | 2002/0188377 A1 | 11-14-2002 | Schaetzl | |
| | 340 | 2002/0162129 A1 | 10-31-2002 | Lannfelt | |
| | 395 | 2002/0160394 A1 | 10-31-2002 | Wu | |
| | 326 | 2002/0136718 A1 | 09-26-2002 | Raso | |
| | 379 | 2002/0132268 A1 | 09-19-2002 | Chang et al. | |
| | 365 | 2002/0133001 A1 | 09-19-2002 | Geffer et al. | |
| | 325 | 2002/0102281 A1 | 08-01-2002 | Raso | |
| | 362 | 2002/0094335 A1 | 07-18-2002 | Chalfour et al. | |
| | 306 | 6,417,178 B1 | 07-09-2002 | Klunk et al. | |
| | 376 | 2002/0086847 A1 | 07-04-2002 | Chain | |
| | 345 | 2002/0077288 A1 | 06-20-2002 | Frangione | |
| | 405 | 6,399,314 B1 | 06-04-2002 | Krishnamurthy | |
| | 453 | 2002/0058267 A1 | 05-18-2002 | Ozenberger et al. | |
| | 342 | 2002/0009445 A1 | 01-24-2002 | Du et al. | |
| CW | 511 | 6,331,440 | 12-18-2001 | Nordstedt, et al. | |

Examiner
SignatureDate
Considered

09/15/2005

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
60475801 v1

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-----------------|
| Application Number | 10/823,463 |
| Filing Date | April 12, 2004 |
| First Named Inventor | Schenk, D. B. |
| Art Unit | 1647 |
| Examiner Name | Nichols, C. J. |
| Attorney Docket Number | 15270J-004754US |

| Sheet | 2 | of | 31 |
|--------------------|-----------------|------------|----------------------|
| 416 | 6,303,567 B1 | 10-16-2001 | Findels et al. |
| 267 | 6,294,171 B2 | 09-25-2001 | McMichael |
| 381 | 2001/0021769 A1 | 09-13-2001 | Prusiner |
| 401 | 6,284,533 B1 | 09-04-2001 | Thomas |
| 234 | 6,284,221 B1 | 08-04-2001 | Schenk, et al. |
| 300 | 2001/0018053 A1 | 08-30-2001 | McMichael |
| 518 | 6,261,669 | 07-17-2001 | Comis et al. |
| 230 | 6,262,335 B1 | 07-17-2001 | Hsiao et al. |
| 452 | 6,218,508 B1 | 04-17-2001 | Kraft et al. |
| 196 | 6,150,091 | 11-21-2000 | Pandolfo et al. |
| 231 | 6,114,133 | 09-05-2000 | Seubert et al. |
| 1 | 6,057,387 | 05-02-2000 | Stamler et al. |
| 510 | 6,022,859 | 02-08-2000 | Kiessling, et al. |
| 221 | 5,989,566 | 11-23-1999 | Cobb et al. |
| 417 | 5,985,242 | 11-16-1999 | Findels et al. |
| 2 | 5,958,883 | 09-28-1999 | Snow |
| 3 | 5,955,317 | 09-21-1999 | Suzuki et al. |
| 4 | 5,955,079 | 09-21-1999 | Mond et al. |
| 348 | 5,935,927 | 08-10-1999 | Vitek et al. |
| 512 | 5,891,991 | 04-06-1999 | Wasco et al. |
| 5 | 5,877,389 | 03-02-1999 | Hsiao et al. |
| 6 | 5,869,093 | 02-08-1999 | Weiner et al. |
| 7 | 5,868,054 | 02-09-1999 | Weiner et al. |
| 445 | 5,854,215 | 12-29-1998 | Findels et al. |
| 8 | 5,854,204 | 12-29-1998 | Findels et al. |
| 9 | 5,851,896 | 12-22-1998 | Kline |
| 10 | 5,849,298 | 12-15-1998 | Weiner et al. |
| 382 | 5,846,533 | 12-08-1998 | Prusiner |
| 321 | 5,837,672 | 11-17-1998 | Schenk et al. |
| 11 | 5,837,473 | 11-17-1998 | Maggio et al. |
| 353 | 5,824,322 | 10-20-1998 | Balasubramanian |
| 448 | 5,817,628 | 10-06-1998 | Findels et al. |
| 12 | 5,788,180 | 07-28-1998 | Konig et al. |
| 207 | 5,780,587 | 07-14-1998 | Potter |
| 357 | 5,778,468 B1 | 07-07-1998 | Hauser et al. |
| 451 | 5,766,846 | 08-18-1998 | Schlossmacher et al. |
| 13 | 5,753,824 | 03-19-1998 | McMichael et al. |
| Examiner Signature | <i>Chang</i> | | Date Considered |
| | | | 09/15/2005 |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
60475801 v1

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0851-0001

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-----------------|
| Application Number | 10/823,463 |
| Filing Date | April 12, 2004 |
| First Named Inventor | Schenk, D. B. |
| Art Unit | 1647 |
| Examiner Name | Nichols, C. J. |
| Attorney Docket Number | 16270J-004754US |

Sheet 3 of 31

| | | | |
|-----|--------------|------------|---------------------|
| 380 | 5,750,361 | 05-12-1998 | Prusiner et al. |
| 14 | 6,750,349 | 05-12-1998 | Suzuki et al. |
| 197 | 5,744,368 | 04-28-1998 | Goldhaber et al. |
| 211 | 5,738,142 | 04-07-1998 | Sette et al. |
| 15 | 5,733,547 | 03-31-1998 | Weiner et al. |
| 373 | 5,721,130 | 02-24-1998 | Seubert et al. |
| 16 | 5,688,651 | 11-18-1997 | Solomon |
| 17 | 5,679,348 | 10-21-1997 | Nesburn et al. |
| 515 | 5,652,334 | 07-29-1997 | Roberts |
| 18 | 5,645,820 | 07-08-1997 | Hafler et al. |
| 19 | 5,641,474 | 06-24-1997 | Hafler et al. |
| 20 | 5,641,473 | 06-24-1997 | Hafler et al. |
| 356 | 5,622,701 | 04-22-1997 | Berg |
| 21 | 5,612,488 | 03-18-1997 | McConlogue et al. |
| 22 | 5,605,811 | 02-25-1997 | Seubert et al. |
| 320 | 5,593,848 | 01-14-1997 | Schenk et al. |
| 23 | 5,585,100 | 12-17-1996 | Mond et al. |
| 358 | 5,583,112 B2 | 12-10-1996 | Kensil et al. |
| 574 | 5,576,184 | 11-19-1996 | Better et al. |
| 24 | 5,571,500 | 11-05-1996 | Hafler et al. |
| 25 | 5,571,499 | 11-05-1996 | Hafler et al. |
| 513 | 5,514,548 | 05-07-1996 | Krebbert et al. |
| 514 | 5,470,951 | 11-28-1995 | Roberts |
| 403 | 5,464,823 | 11-07-1995 | Lehrer et al. |
| 175 | 5,441,870 | 08-15-1995 | Seubert, et al. |
| 26 | 5,434,170 | 07-18-1995 | Andrusis, Jr. |
| 27 | 5,387,742 | 02-07-1995 | Cordell |
| 543 | 5,278,049 | 01-11-1994 | Baker et al. |
| 181 | 5,270,165 | 12-14-1993 | Van Nostrand et al. |
| 284 | 5,231,170 | 07-27-1993 | Averback |
| 28 | 5,231,000 | 07-27-1993 | Majocha et al. |
| 29 | 5,220,013 | 06-15-1993 | Ponte et al. |
| 30 | 5,208,038 | 05-04-1993 | Eppstein et al. |
| 31 | 5,192,753 | 03-09-1993 | McGeer et al. |
| 32 | 5,187,153 | 02-16-1993 | Cordell et al. |
| 548 | 5,098,706 | 03-17-1992 | Flint |

Examiner
Signature

chang-y

Date
Considered

09/15/2005

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Applicant's unique citation designation number (optional). * Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231 60475801 v1

PTO/SB/02A (10-01)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 31

Complete if Known

| | |
|------------------------|-----------------|
| Application Number | 10/823,463 |
| Filing Date | April 12, 2004 |
| First Named Inventor | Schenk, D. B. |
| Art Unit | 1647 |
| Examiner Name | Nichols, C. J. |
| Attorney Docket Number | 15270J-004754US |

| | | | | | |
|-----|-----|-----------|------------|------------------|--|
| CyW | 33 | 5,057,540 | 10-15-1991 | Kensu et al. | |
| | 198 | 5,004,697 | 04-20-1991 | Pardridge | |
| | 570 | 4,912,208 | 03-27-1990 | Goldhaber et al. | |
| | 402 | 4,713,366 | 12-15-1987 | Stevens | |
| CyW | 34 | 4,666,829 | 05-19-1987 | Glenner et al. | |

U.S. PATENT APPLICATIONS

| Examiner | Cite No. ¹ | Document Number Number Kind Code ² (if known) | Filing Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|----------|-----------------------|---|---------------------------|--|---|
| CyW | 296 | 60/254,465 | 12-08-2000 | Holtzman et al. | |
| | 297 | 60/254,498 | 12-08-2000 | Holtzman et al. | |
| | 306 | 09/724,842 | 11-28-2000 | Chalfour et al. | |
| | 299 | 60/188,295 | 03-01-2000 | Rasmussen et al. | |
| | 295 | 60/184,601 | 02-24-2000 | Holtzman et al. | |
| | 282 | 60/169,867 | 12-08-1999 | Chain | |
| | 242 | 60/168,594 | 11-29-1999 | Chalfour et al. | |
| CyW | 283 | 08/441,140 | 11-16-1999 | Solomon et al. | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials ¹ | Cite No. ¹ | Foreign Patent Document | | | Publication Date MM-DD- YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁴ |
|-----------------------------------|--------------------------|---------------------------|---------------------|--------------------------------------|------------------------------------|---|---|----------------|
| | | Country Code ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| CyW | 533 | AU | 199870091 | | 07-01-1999 | | | |
| | 343 | EP | 1 172 378 | A1 | 01-16-2002 | | | |
| | 48 | EP | 508 785 | B1 | 03-15-2000 | | | |
| | 43 | EP | 639 081 | B1 | 11-03-1999 | | | |
| | 46 | EP | 561 087 | B1 | 08-04-1999 | | | |
| | 35 | EP | 911 036 | A2 | 04-28-1999 | | | |
| | 42 | EP | 652 962 | B1 | 12-16-1998 | | | |
| | 36 | EP | 868 918 | A2 | 10-07-1998 | | | |
| | 37 | EP | 863 211 | A1 | 09-09-1998 | | | |
| | 38 | EP | 845 270 | A1 | 08-03-1998 | | | |
| | 523 | EP | 752 886 | B1 | 01-28-1998 | | | |
| | 45 | EP | 594 607 | B1 | 08-27-1997 | | | |
| | 39 | EP | 782 859 | A1 | 07-09-1997 | | | |
| CyW | 187 | EP | 783 104 | A1 | 07-09-1997 | | | |

Examiner
Signature

Chang

Date
Considered

09/15/2005

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231 60475801 v1

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. CMB 0651-0051

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 31

Complete if Known

| | |
|------------------------|-----------------|
| Application Number | 10/823,463 |
| Filing Date | April 12, 2004 |
| First Named Inventor | Schenk, D. B. |
| Art Unit | 1647 |
| Examiner Name | Nichols, C. J. |
| Attorney Docket Number | 15270J-004754US |

| | | | | | | | |
|-----|----|-----------|--------|------------|--|--|-----|
| 47 | EP | 526 511 | B1 | 05-28-1997 | | | |
| 50 | EP | 440 619 | B1 | 01-24-1996 | | | |
| 51 | EP | 359 783 | B1 | 11-29-1995 | | | |
| 40 | EP | 683 234 | A1 | 11-22-1995 | | | |
| 41 | EP | 666 080 | A1 | 08-09-1995 | | | |
| 44 | EP | 613 007 | A2 | 08-31-1994 | | | |
| 52 | EP | 278 723 | B1 | 12-08-1993 | | | Yes |
| 49 | EP | 451 700 | A1 | 10-16-1991 | | | |
| 93 | GB | 2 335 192 | A | 09-15-1999 | | | |
| 92 | GB | 2 220 211 | A | 01-04-1990 | | | |
| 579 | WO | 04/031400 | A2 | 04-16-2004 | | | |
| 571 | WO | 04/13172 | A2, A3 | 02-12-2004 | | | |
| 443 | WO | 03/074081 | A1 | 09-12-2003 | | | |
| 447 | WO | 03/051374 | A2 | 08-26-2003 | | | |
| 433 | WO | 03/020212 | A2 | 03-13-2003 | | | |
| 458 | WO | 02/060481 | A1 | 08-08-2002 | | | |
| 457 | WO | 02/048237 | A1 | 06-13-2002 | | | |
| 351 | WO | 02/34878 | A2 | 05-02-2002 | | | |
| 557 | WO | 02/88307 | A2 | 11-07-2002 | | | |
| 556 | WO | 02/88306 | A2 | 11-07-2002 | | | |
| 352 | WO | 02/34777 | A1 | 05-02-2002 | | | |
| 466 | WO | 02/021141 | A2 | 03-14-2002 | | | |
| 341 | WO | 02/03911 | A2 | 01-17-2002 | | | |
| 344 | WO | 01/90182 | A2 | 11-29-2001 | | | |
| 348 | WO | 01/77167 | A2 | 10-18-2001 | | | |
| 294 | WO | 01/82801 | A2 | 08-30-2001 | | | |
| 301 | WO | 01/82284 | A2 | 08-30-2001 | | | |
| 298 | WO | 01/42306 | A2 | 08-14-2001 | | | |
| 243 | WO | 01/39798 | A2 | 08-07-2001 | | | |
| 450 | WO | 01/18169 | A3 | 03-15-2001 | | | |
| 455 | WO | 01/10900 | A2 | 02-15-2001 | | | |
| 199 | WO | 00/77178 | A1 | 12-21-2000 | | | |
| 322 | WO | 00/72880 | A2, A3 | 12-07-2000 | | | |
| 323 | WO | 00/72876 | A2, A3 | 12-07-2000 | | | |
| 324 | WO | 00/72870 | A1 | 12-07-2000 | | | |
| 629 | WO | 00/68263 | A2 | 11-16-2000 | | | |
| 240 | WO | 00/43039 | A1 | 07-27-2000 | | | |

Examiner
Signature

Chang

Date
Considered

09/15/2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231 60475801 v1

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-----------------|
| Application Number | 10/823,463 |
| Filing Date | April 12, 2004 |
| First Named Inventor | Schenk, D. B. |
| Art Unit | 1847 |
| Examiner Name | Nichols, C. J. |
| Attorney Docket Number | 16270J-004764US |

Sheet 6 of 31

| | | | | | | | |
|-----|-----|----|----------|----|------------|--|--|
| CYW | 188 | WO | 00/43049 | A1 | 07-27-2000 | | |
| | 518 | WO | 00/28238 | A2 | 05-11-2000 | | |
| | 555 | WO | 00/23082 | A1 | 04-27-2000 | | |
| | 522 | WO | 00/20027 | A2 | 04-13-2000 | | |
| | 53 | WO | 99/80024 | A1 | 11-25-1999 | | |
| | 55 | WO | 99/58564 | A1 | 11-18-1999 | | |
| | 54 | WO | 99/80021 | A2 | 11-15-1999 | | |
| | 331 | WO | 99/06545 | A2 | 11-02-1999 | | |
| | 57 | WO | 98/27949 | A1 | 06-10-1999 | | |
| | 58 | WO | 99/27944 | A1 | 06-10-1999 | | |
| | 59 | WO | 99/27911 | A1 | 06-10-1999 | | |
| | 526 | WO | 98/06687 | A2 | 02-11-1999 | | |
| | 56 | WO | 98/06086 | A2 | 02-11-1999 | | |
| | 203 | WO | 99/00150 | A2 | 01-07-1999 | | |
| | 60 | WO | 98/44955 | A1 | 10-15-1998 | | |
| | 454 | WO | 98/33815 | A1 | 09-06-1998 | | |
| | 520 | WO | 98/22120 | A1 | 05-28-1998 | | |
| | 530 | WO | 98/08868 | A1 | 03-05-1998 | | |
| | 61 | WO | 98/07890 | A2 | 02-26-1998 | | |
| | 521 | WO | 98/05350 | A1 | 02-12-1998 | | |
| | 525 | WO | 98/02482 | A1 | 01-22-1998 | | |
| | 527 | WO | 97/32017 | A1 | 09-04-1997 | | |
| | 202 | WO | 97/21728 | A1 | 06-19-1997 | | |
| | 62 | WO | 97/17613 | A1 | 05-15-1997 | | |
| | 383 | WO | 97/10505 | A1 | 03-20-1997 | | |
| | 528 | WO | 97/08320 | A1 | 03-06-1997 | | |
| | 63 | WO | 96/39176 | A1 | 12-12-1996 | | |
| | 532 | WO | 96/37621 | A2 | 11-28-1996 | | |
| | 208 | WO | 96/28471 | A1 | 09-19-1996 | | |
| | 64 | WO | 96/25435 | A1 | 08-22-1996 | | |
| | 65 | WO | 96/18900 | A1 | 06-20-1996 | | |
| | 66 | WO | 95/31996 | A1 | 11-30-1995 | | |
| | 518 | WO | 95/23166 | A1 | 08-31-1995 | | |
| | 200 | WO | 95/12815 | A1 | 05-11-1995 | | |
| | 67 | WO | 95/11994 | A1 | 05-04-1995 | | |
| | 68 | WO | 95/11311 | A1 | 04-27-1995 | | |
| | 227 | WO | 95/11008 | A2 | 04-27-1995 | | |
| CYW | 531 | WO | 95/08999 | A1 | 04-06-1995 | | |

Examiner
Signature

Changy

Date
Considered

09/15/2005

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
60475801 v1

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete If Known

| | |
|------------------------|-----------------|
| Application Number | 10/823,483 |
| Filing Date | April 12, 2004 |
| First Named Inventor | Schenk, D. B. |
| Art Unit | 1647 |
| Examiner Name | Nichols, C. J. |
| Attorney Docket Number | 15270J-004754US |

| Sheet | 7 | of | 31 | Attorney Docket Number | | 15270J-004754US | | |
|-------|-----|----|----------|------------------------|------------|-----------------|--------------------------|--|
| C/W | 69 | WO | 95/05853 | A1 | 03-02-1995 | | | |
| | 524 | WO | 95/05393 | A2 | 02-23-1995 | | <input type="checkbox"/> | |
| | 70 | WO | 95/04151 | A2 | 02-09-1995 | | | |
| | 201 | WO | 94/28412 | A1 | 12-08-1994 | | | |
| | 817 | WO | 94/05311 | A1 | 03-17-1994 | | | |
| | 71 | WO | 94/03615 | A1 | 02-17-1994 | | | |
| | 72 | WO | 94/01772 | A1 | 01-20-1994 | | | |
| | 73 | WO | 93/21950 | A1 | 11-11-1993 | | | |
| | 74 | WO | 93/16724 | A1 | 09-02-1993 | | | |
| | 75 | WO | 93/15760 | A1 | 08-19-1993 | | | |
| | 76 | WO | 93/14200 | A1 | 07-22-1993 | | | |
| | 205 | WO | 93/04194 | A1 | 03-04-1993 | | | |
| | 77 | WO | 93/02189 | A1 | 02-04-1993 | | | |
| | 78 | WO | 92/13069 | A1 | 08-06-1992 | | | |
| | 79 | WO | 92/06708 | A1 | 04-30-1992 | | | |
| | 80 | WO | 92/06187 | A1 | 04-16-1992 | | | |
| | 81 | WO | 91/19810 | A1 | 12-28-1991 | | | |
| | 82 | WO | 91/16819 | A1 | 11-14-1991 | | | |
| | 83 | WO | 91/12816 | A1 | 09-05-1991 | | | |
| | 84 | WO | 91/08760 | A1 | 06-27-1991 | | | |
| | 85 | WO | 90/12871 | A1 | 11-01-1990 | | | |
| | 86 | WO | 90/12870 | A1 | 11-01-1990 | | | |
| | 89 | WO | 89/08689 | A1 | 07-27-1989 | | | |
| | 88 | WO | 89/06242 | A1 | 07-13-1989 | | | |
| | 90 | WO | 89/03687 | A1 | 05-05-1989 | | | |
| | C/W | 87 | WO | 89/01343 | A1 | 02-23-1989 | | |
| | | 91 | WO | 88/10120 | A1 | 12-29-1988 | | |

| | | | |
|-----------------------|-----------------|--------------------|------------|
| Examiner Signature | <i>Cheng-Yu</i> | Date Considered | 09/15/2005 |
|-----------------------|-----------------|--------------------|------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231
60475801 v1

PTO/SB/08D (10-01)

Approved for use through 10/31/2002. OMB 0951-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 8 of 31

Complete if Known

| | |
|------------------------|-----------------|
| Application Number | 10/823,483 |
| Filing Date | April 12, 2004 |
| First Named Inventor | Schenk, D. B. |
| Art Unit | 1847 |
| Examiner Name | Nichols, C. J. |
| Attorney Docket Number | 15270J-004754US |

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|---|--------------------------|
| Cyw | 391 | AGUZZI et al., "Prion research: the next frontiers," <i>Nature</i> , 389:795-798 (1997). | |
| | 372 | AKIYAMA et al., "Occurrence of the Diffuse Amyloid β -Protein (A β) Deposits With Numerous A β -Containing Glial Cells in the Cerebral Cortex of Patients With Alzheimer's Disease," <i>Glia</i> , 25:324-331 (1999). | |
| | 393 | AKIYAMA et al., "Inflammation and Alzheimer's disease," <i>Neurobiology of Aging</i> , 21:383-421 (2000). | |
| | 94 | ANDERSEN et al., "Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?", <i>Neurology</i> , 45:1441-1445 (1995). | <input type="checkbox"/> |
| | 448 | ANDREW et al., <i>Current Protocols in Immunology</i> , 2.7.1-2.9.8, John Wiley & Sons, Inc. (1997). | |
| | 484 | ARENDIAH et al., "Behavioral assessment of Alzheimer's transgenic mice following long-term A β vaccination: Task specificity and correlations between A β deposition and spatial memory," <i>DNA and Cell Biology</i> , 20(11):737-744 (2001). | |
| | 95 | Associated Press, "Immune cells may promote Alzheimer's, a study finds," <i>The Boston Globe</i> (4/13/95). | <input type="checkbox"/> |
| | 485 | BACSKAI et al., "Imaging of amyloid- β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy," <i>Nature Medicine</i> , 7(3):369-372 (2001). | |
| | 504 | BALBACH et al., "Amyloid fibril formation by A β_{1-42} , a seven-residue fragment of the Alzheimer's β -amyloid peptide, and structural characterization by solid state NMR," <i>Biochemistry</i> , 39:13748-13759 (2000). | |
| | 176 | BARD et al., "Peripherally administered antibodies against amyloid β -peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," <i>Nature Medicine</i> , 6(8):916-919 (2000). | <input type="checkbox"/> |
| | 550 | BARD et al., "Epitope and isotype specificities of antibodies to β -amyloid peptide for protection against Alzheimer's disease-like neuropathology," <i>PNAS</i> , 100(4):2023-2028 (2003). | |
| | 228 | BARROW et al., "Solution Conformations and aggregational Properties of Synthetic Amyloid Beta-Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra," <i>J. Mol. Biol.</i> , 225(4):1075-1093 (1992). | |
| Cyw | 96 | BAUER et al., "Interleukin-6 and α -2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," <i>FEBS Letters</i> , 285(1):111-114 (1991). | <input type="checkbox"/> |

Examiner
Signature

Chang

Date
Considered

09/15/2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60475801 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|---|--------------------------|-----------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/823,463 |
| | | Filing Date | April 12, 2004 |
| | | First Named Inventor | Schenk, D. B. |
| | | Art Unit | 1647 |
| | | Examiner Name | Nichols, C. J. |
| | | Attorney Docket Number | 15270J-004754US |
| Sheet | 8 | of | 31 |

| | | | |
|----|-----|--|--------------------------|
| Cy | 239 | BEASLEY, "Alzheimer's traced to proteins caused by aging," Reuters, April 20, 2001 7:56 PM ET. | |
| | 561 | BELLOTTI et al., "Application of Monoclonal Anti-idiotypes in the Study of AL Amyloidosis: Therapeutic Implications," <u>Renal Failure</u> , 15(3):365-371 (1999). | |
| | 404 | BENJAMINI et al., from <u>IMMUNOLOGY A Short Course</u> , Second Edition, Chapter 4, Antibody Structure, pages 49-65, 1991, published by Wiley-Liss, Inc., New York, New York. | |
| | 558 | BENJAMINI et al., from <u>IMMUNOLOGY A Short Course</u> , Second Edition, pages 138-138, 143, 73-74, 372-373, and 400-401, 1991, published by Wiley-Liss, Inc., New York, New York. | |
| | 540 | BENKIRANE, et al., "Antigenicity and Immunogenicity of Modified Synthetic Peptides Containing D-Amino Acid Residues," <u>J. Biol. Chem.</u> , 268(23):26279-26285 (1993). | |
| | 204 | BERCOVICI et al., "Chronic Intravenous Injections of Antigen Induce and Maintain Tolerance in T Cell Receptor-Transgenic Mice," <u>Eur. J. Immunol.</u> , 29:345-354 (1999). | |
| | 212 | BICKEL et al., "Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheimer's Diseases," <u>Soc. for Neuroscience Abstracts</u> , 18:764 (1992). | |
| | 97 | BLASS, "Immunologic Treatment of Alzheimer's Disease," <u>New England J. Medicine</u> , 341(22):1694 (1999). | <input type="checkbox"/> |
| | 98 | BODMER et al., "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," <u>Biochem. Biophys. Res. Comm.</u> , 171(2):890-897 (1990). | <input type="checkbox"/> |
| | 99 | BORCHELT et al., "Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins," <u>Neuron</u> , 19:939-945 (1997). | <input type="checkbox"/> |
| | 100 | BORIS-LAWRIE et al., "Recent advances in retrovirus vector technology," <u>Curr. Opin. Genetic Develop.</u> , 3:102-109 (1993). | <input type="checkbox"/> |
| | 419 | BORK et al., "Go hunting in sequence databases but watch out for the traps," <u>Trends in Genetics</u> , 12(10):425-427 (1996). | |
| | 418 | BORK, P., "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle," <u>Genome Research</u> , 10:398-400 (2000). | |
| | 420 | BRENNER, S. E., "Errors in genome annotation," <u>Trends in Genetics</u> , 15(4):132-133 (1999). | |
| Cy | 101 | BRICE et al., "Absence of the amyloid precursor protein gene mutation (APP717 : Val>Ile) in 85 cases of early onset Alzheimer's disease," <u>J. Neurology, Neurosurg. Psychiatry</u> , 56:112-115 (1993). | <input type="checkbox"/> |

| | | | |
|--------------------|--------------|-----------------|----------|
| Examiner Signature | <i>Chang</i> | Date Considered | 09/15/05 |
|--------------------|--------------|-----------------|----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60475801 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|------------------------|--------------------------|----------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/823,463 |
| | | Filing Date | April 12, 2004 |
| | | First Named Inventor | Schenk, D. B. |
| | | An Unit | 1647 |
| | | Examiner Name | Nichols, C. J. |
| Sheet 10 of 31 | Attorney Docket Number | 15270J-004754US | |

| | | | |
|-----|-----|--|--------------------------|
| CyW | 461 | BURDICK et al., "Assembly and aggregation properties of synthetic Alzheimer's A β amyloid peptide antigens," <u>J. Biol. Chem.</u> , 267:546-555 (1992). | |
| | 327 | CAMERON, "Recent Advances in Transgenic Technology," <u>Molecular Biotechnology</u> , 7:263-265 (1997). | |
| | 285 | CAPUTO et al., "Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease," <u>Clin. Neurochem.</u> , 15:414A-414B (1992). | |
| | 421 | CASTILLO et al., "Amylin / Islet Amyloid Polypeptide: Biochemistry, Physiology, Patho-Physiology," <u>Diabetes & Metabolism (Paris)</u> , 21:3-25 (1995). | |
| | 224 | Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Thimerosal in Vaccines (Mercury in Plasma-Derived Products), web site contents found at: http://www.fda.gov/cber/vaccine/thimerosal.htm , last updated May 16, 2002. | |
| | 102 | CHAO et al., "Transforming Growth Factor- β Protects human Neurons Against β -Amyloid-Induced Injury," <u>Soc. Neurosci. Abstracts</u> , 19:513-7 (1993). | <input type="checkbox"/> |
| | 266 | CHAPMAN, "Model behavior," <u>Nature</u> , 408:915-916 (2000). | |
| | 349 | CHECK, "Battle of the Mind," <u>Nature</u> , 422:370-372 (2003). | |
| | 222 | Chemical Abstract database, Abstract of "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals," Chemical Abstract database. (Publication date unknown.) | |
| | 332 | CHEN et al., "Neurodegenerative Alzheimer-like pathology in PDAPP 717V \rightarrow F transgenic mice," <u>Progress in Brain Research</u> , 117:327-337 (1998). | |
| | 307 | CHEN et al., "A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease," <u>Nature</u> , 408(6815):975-979 (2000). | |
| | 213 | CHEN et al., "An Antibody to β Amyloid Precursor Protein Inhibits Cell-substratum Adhesion in Many Mammalian Cell Types," <u>Neuroscience Letters</u> , 125:223-226 (1991). | |
| | 542 | CHISHTI et al., "Early-onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695," <u>J. Biol. Chem.</u> , 276(24):21562-70 (2001). | |
| | 566 | CHOTHIA et al., "Domain Association in Immunoglobulin Molecules," <u>J. Mol. Biol.</u> , 186:651-663 (1985). | |
| CyW | 302 | CHUNG et al., "Uptake, Degradation, and Release of Fibrillar and Soluble Forms of Alzheimer's Amyloid β -Peptide by Microglial Cells," <u>J. Biol. Chem.</u> , 274(45):32301-32308 (1999). | |

| | | | |
|--------------------|--------------|-----------------|----------|
| Examiner Signature | <i>Chang</i> | Date Considered | 09/15/05 |
|--------------------|--------------|-----------------|----------|

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60475801 v1

PTO/S0.088 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1448B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 11 of 31

Complete if Known

| | |
|------------------------|-----------------|
| Application Number | 10/823,463 |
| Filing Date | April 12, 2004 |
| First Named Inventor | Schenk, D. B. |
| Art Unit | 1847 |
| Examiner Name | Nichols, C. J. |
| Attorney Docket Number | 15270J-004754US |

| | | | |
|-----|-----|--|--|
| Cyw | 509 | CIRrito et al., "Amyloid β and Alzheimer disease therapeutics: the devil may be in the details," <u>J. Clin. Invest.</u> , 112:321-323 (2000). | |
| | 462 | CO et al., "Chimeric and humanized antibodies with specificity for the CD33 antigen," <u>J. Immunol.</u> , 148:1149-1154 (1992). | |
| | 291 | COLOMA et al., "Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor," <u>Pharm. Res.</u> , 17:268-274 (2000). | |
| | 333 | CONWAY et al., "Acceleration of oligomerization, not fibrilization, is a shared property of both α -synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy," <u>PNAS</u> , 97(2):571-576 (2000). | |
| | 286 | CORDELL, B., "A β -Amyloid formation as a potential therapeutic target for Alzheimer's disease," <u>Ann. Rev. Pharmacol. Toxicol.</u> , 34:69-89 (1994). | |
| | 287 | COSTA et al., "Immunoassay for transthyretin variants associated with amyloid neuropathy," <u>Scand. J. Immunol.</u> , 38:177-182 (1993). | |
| | 541 | CRIBBS et al., "All-D-Erantomers of Beta-Amyloid Exhibit Similar Biological Properties to All-L-Beta-Amyloids," <u>J. Biol. Chem.</u> , 272:7431-7436 (1997). | |
| | 293 | DALY, et al., "Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's Disease brain," <u>Life Sci.</u> , 63:2121-2131 (1998). | |
| | 412 | DAS et al., "Amyloid- β Immunization Effectively Reduces Amyloid Deposition in FcR γ Knock-Out Mice," <u>J. Neuroscience</u> , 23(24):8532-8538 (2003). | |
| | 468 | DEMATTOIS et al., "Peripheral anti-A β antibody alters CNS and plasma clearance and decreases A β burden in a mouse model of Alzheimer's disease," <u>PNAS</u> , 98(15):8850-8855 (2001). | |
| | 214 | DEMATTOIS et al., "Peripheral Anti A β Antibody Alters CNS And Plasma A β Clearance and Decreases Brain A β Burden in a Mouse Model of Alzheimer's Disease," <u>PNAS early edition</u> , 10.1073/pnas.151261398 (2001). | |
| | 493 | DEMATTOIS et al., "Plaque-associated disruption of CSF and plasma amyloid- β (A β) equilibrium in a mouse model of Alzheimer's disease," <u>J. Neurochem.</u> , 81:229-238 (2002). | |
| | 220 | Dialog/Derwent, Abstract of WPI Acc No: 1997-054438/199706: Stable vaccine compns. - comprise a macrocyclic lactone, a milbemycin, an avermectin, an antigen, a dispersing agent, an adjuvant, a water sol. organic solvent and saline or water, Derwent File 351: Derwent WPI database. (Publication date unknown.) | |
| Cyw | 486 | DICKEY et al., "Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated β -amyloid 1-42 peptide," <u>DNA and Cell Biology</u> , 20(11):723-729 (2001). | |

Examiner
Signature

Chang

Date
Considered

29/15/2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60475801 v1


PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|------------------------|--------------------------|----------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/823,463 |
| | | Filing Date | April 12, 2004 |
| | | First Named Inventor | Schenk, D. B. |
| | | Art Unit | 1647 |
| | | Examiner Name | Nichols, C. J. |
| Sheet 12 of 31 | Attorney Docket Number | 15270J-004764US | |

| | | | |
|----|-----|--|--|
| CW | 436 | DICKSON et al., "Neuroimmunology of Alzheimer's disease: a conference report," <u>Neurobiology of Aging</u> , 13(6):793-798 (1992), abstract only | |
| | 380 | DIOMEDE et al., "Activation effects of a prion protein fragment (PrP-(106-126)) on human leucocytes," <u>Biochem. J.</u> , 320:563-570 (1996). | |
| | 383 | DODART, "Immunotherapy for Alzheimer's disease: will vaccination work?," <u>Trends in Molecular Medicine</u> , 9(3):85-87 (2003). | |
| | 422 | DOERKS et al., "Protein annotation: detective work for function prediction," <u>Trends in Genetics</u> , 14(8):248-250 (1998). | |
| | 318 | DU et al., "Reduced levels of amyloid beta-peptide antibody in Alzheimer disease," <u>Neurology</u> , 57(5):801-5 (2001). | |
| | 103 | DUFF et al., "Mouse model made," <u>Nature</u> , 373:476-477 (1995). | |
| | 288 | DUMERY et al., "β-Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease," <u>Pathol. Biol.</u> , 49:72-85 (2001). | |
| | 407 | ECK et al., <u>Goodman and Gilman's The pharmacological basis of therapeutics</u> , Chapter 6, pages 77-101 (1996). | |
| | 475 | EL-AGNAF et al., "The influence of the central region containing residues 19-25 on the aggregation properties and secondary structure of Alzheimer's beta-amyloid peptide," <u>Eur. J. Biochem.</u> , 256(3):560-569 (1998). | |
| | 225 | Elian, "Elián and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792," Press Release. (1/18/2002). | |
| | 226 | Elián, "Elián and Wyeth Provide Update on Status of Alzheimer's Collaboration," Press Release (3/1/2002). | |
| | 104 | ELIZAN et al., "Antineurofilament antibodies in a postencephalitic and idiopathic Parkinson's disease," <u>J. Neurol. Sciences</u> , 59:341-347 (1983). | |
| | 289 | ESIRI, "Is an effective immune intervention for Alzheimer's disease in prospect?," <u>Trends in Pharm. Sci.</u> , 22:2-3 (2001). | |
| | 501 | ESLER et al., "Point substitution in the central hydrophobic cluster of a human β-amyloid congener disrupts peptide folding and abolishes plaque competence," <u>Biochemistry</u> , 35:13914-13921 (1996). | |
| CW | 105 | FELSENSTEIN et al., "Processing of the β-amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," <u>Neuroscience Letters</u> , 162:185-189 (1993). | |

| | | | |
|--------------------|---|-----------------|----------|
| Examiner Signature |  | Date Considered | 09/15/05 |
|--------------------|---|-----------------|----------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60475801 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002, OMB 0951-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|----|--------------------------|-----------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/823,483 |
| | | Filing Date | April 12, 2004 |
| | | First Named Inventor | Schenk, D. B. |
| | | Art Unit | 1847 |
| | | Examiner Name | Nichols, C. J. |
| | | Attorney Docket Number | 15270J-004754US |
| Sheet | 13 | of | 31 |

| | | |
|----|-----|---|
| Cy | 328 | FELSENSTEIN et al., "Transgenic Rat and In-Vitro Studies of B-Amyloid Precursor Protein Processing," <i>Alzheimer's and Parkinson's Diseases</i> , Hanin et al. Ed., pp 401-409, Plenum Press, New York, (1995). |
| | 106 | FINCH et al., "Evolutionary Perspectives on Amyloid and Inflammatory Features of Alzheimer Disease," <i>Neurobiology of Aging</i> , 17(5):809-815 (1996). |
| | 539 | FINDEIS et al., "Modified peptide inhibitors of amyloid B-peptide polymerization," <i>Biochemistry</i> , 38:6791-6800 (1999). |
| | 107 | FISHER et al., "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," <i>PNAS</i> , 88:1779-1782 (1991). |
| | 108 | FLANDERS et al., "Altered expression of transforming growth factor- β in Alzheimer's disease," <i>Neurology</i> , 45:1561-1569 (1995). |
| | 464 | FLOOD et al., "An amyloid β -Protein fragment, A β (12-28), equipotently impairs post-training memory processing when injected into different limbic system structures," <i>Brain Res.</i> 663(2):271-276 (1994). |
| | 538 | FLOOD, et al., "Topography of a binding site for small amnesic peptides deduced from structure-activity studies: Relation to amnesic effect of amyloid B protein," <i>PNAS</i> , 91:380-384 (1994). |
| | 423 | FONSECA et al., "The Presence of Isoaspartic Acid in β -Amyloid Plaques Indicates Plaque Age," <i>Experimental Neurology</i> , 157(2):277-288 (1999). |
| | 386 | FRAUTSCHY et al., "Effects of injected Alzheimer β -amyloid cores in rat brain," <i>PNAS</i> , 88:8362-8366 (1991). |
| | 565 | FRAZER et al., "Immunoglobulins: Structure and Function," chapter 3, pages 37-74 from <i>Fundamental Immunology</i> , fourth edition, W.E. Paul, eds., Lippincott-Raven publishers, Philadelphia (1999). |
| | 246 | FRENKEL et al., "Generation of auto-antibodies towards Alzheimer's disease vaccination," <i>Vaccine</i> , 19:2615-2619 (2001). |
| | 245 | FRENKEL et al., "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β -amyloid peptide is essential for modulation of fibrillar aggregation," <i>J. of Neuroimmunology</i> , 95:136-142 (1999). |
| | 247 | FRENKEL et al., "Immunization against Alzheimer's β -amyloid plaques via EFRH phage administration," <i>PNAS</i> , 97:11455-11459 (2000). |
| Cy | 248 | FRENKEL et al., "N-terminal EFRH sequence of Alzheimer's β -amyloid peptide represents the epitope of its anti-aggregating antibodies," <i>J. of Neuroimmunology</i> , 88:85-90 (1998). |

| | | | |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | <i>Chang</i> | Date Considered | 09/15/2005 |
|--------------------|--------------|-----------------|------------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60475801 v1

PTO/SB/019 (10-01)

Approved for use through 10/31/2002. OMB 0851-0051

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|----|--------------------------|-----------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/823,463 |
| | | Filing Date | April 12, 2004 |
| | | First Named Inventor | Schenk, D. B. |
| | | Art Unit | 1847 |
| | | Examiner Name | Nichols, C. J. |
| | | Attorney Docket Number | 15270J-004754US |
| Sheet | 14 | of | 31 |

| | | | |
|-----|-----|---|--|
| CyW | 244 | FRENKEL, et al., "Modulation of Alzheimer's β -amyloid neurotoxicity by site-directed single chain antibody," <i>J. of Neuroimmunology</i> , 108:23-31 (2000). | |
| | 210 | FRIEDLAND et al., "Development of an anti-A β monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease," <i>Mol. Neurology</i> , 9:107-113 (1994). | |
| | 249 | FRIEDLAND, et al., "Neuroimaging of Vessel Amyloid in Alzheimer's Disease," in <i>Cerebrovascular Pathology in Alzheimer's Disease</i> , eds. de la Torre and Hachinski, New York Academy of Sciences, New York, New York (1997). | |
| | 384 | FURLAN et al., "Vaccination with amyloid- β peptide induces autoimmune encephalomyelitis in C67/BL6 mice," <i>Brain</i> , 126:285-291 (2003). | |
| | 109 | GAMES et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F β -amyloid precursor protein," <i>Nature</i> , 373(6514):523-527 (1995). | |
| | 215 | GAMES et al., "Prevention and Reduction of AD-type Pathology in PDAPP Mice Immunized with A β ," <i>Annals of the New York Academy of Science</i> , 920:274-284 (2000). | |
| | 110 | GANDY et al., "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," <i>TIPS</i> , 13:108-113 (1992). | |
| | 251 | GARDELLA et al., "Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA," <i>Biochem. Biophys. Res. Comm.</i> , 173:1292-1298 (1990). | |
| | 111 | GASKIN et al., "Human antibodies reactive with beta-amyloid protein in Alzheimer's disease," <i>J. Exp. Med.</i> , 177:1181-1186 (1993). | |
| | 252 | GEODES, "N-terminus truncated β -amyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzheimer's disease," <i>Neurobiology of Aging</i> , 20:75-79 (1999). | |
| | 483 | GHISO et al., "Epitope map of two polyclonal antibodies that recognize amyloid lesions in patients with Alzheimer's disease," <i>Biochem. J.</i> , 282 (Pt 2):517-522 (1992). | |
| | 470 | GIULIAN et al., "Specific domains of β -amyloid from Alzheimer plaque elicit neuron killing in human microglia," <i>J. Neurosci.</i> , 16 (19):6021-6037 (1996). | |
| | 243 | GIULIAN, et al., "The HHQK Domain of β -Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," <i>J. Biol. Chem.</i> , 273:29719-29726 (1998). | |
| CyW | 112 | GLENN et al., "Skin immunization made possible by cholera toxin," <i>Nature</i> , 391:851 (1988). | |

| | | | |
|-----------------------|--------------|--------------------|------------|
| Examiner Signature | <i>Chang</i> | Date Considered | 09/15/2005 |
|-----------------------|--------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60475801 v1

PTO/SB/033 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|------------------------|--------------------------|----------------|
| Substitute for form 1449B/PTO | | Complete If Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/823,463 |
| | | Filing Date | April 12, 2004 |
| | | First Named Inventor | Schenk, D. B. |
| | | Art Unit | 1847 |
| | | Examiner Name | Nichols, C. J. |
| Sheet 15 of 31 | Attorney Docket Number | 15270J-004754US | |

| | |
|-----|--|
| 114 | GLENNER et al., "Alzheimer's Disease and Downs Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," <u>Biochem. Biophys. Res. Comm.</u> , 122(3): 1131-1135 (1984). |
| 113 | GLENNER et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," <u>Biochem. Biophys. Res. Comm.</u> , 120(3): 885-890 (1984). |
| 115 | GOATE et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," <u>Nature</u> , 349:704-708 (1991). |
| 388 | GOLDFARB et al., "The Transmissible Spongiform Encephalopathies," <u>Ann. Rev. Med.</u> , 46:57-55 (1995). |
| 424 | GOLDSBY et al., "Vaccines," Chapter 18 from <u>Immunology</u> , 4th Edition, W.H. Freeman and Company, New York, pages 449-465 (2000). |
| 397 | GOLDSTEINS et al., "Goldsteins et al., Exposure of cryptic epitopes on transthyretin only in amypoid and in amyloidogenic mutants," <u>PNAS</u> , 96:3108-3113 (1999). |
| 303 | GONZALES-FERNANDEZ et al., "Low antigen dose favors selection of somatic mutants with hallmarks of antibody affinity maturation," <u>Immunology</u> , 93:149-153 (1998). |
| 503 | GOREVIC et al., "Ten to fourteen residue peptides of Alzheimer's disease protein are sufficient for amyloid fibril formation and its characteristic X ray diffraction pattern" <u>Biochem. and Biophys. Res. Commun.</u> , 147(2):854-862 (1987). |
| 237 | GORTNER, <u>Outlines of Biochemistry</u> , pp. 322-323, John Wiley & Sons, Inc., New York (1949). |
| 116 | GOZES et al., "Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide," <u>PNAS</u> , 93:427-432 (1996). |
| 190 | GRAVINA et al., "Amyloid β Protein ($A\beta$) in Alzheimer's Disease," <u>J. Biol. Chem.</u> , 270(13):7013-7016 (1995). |
| 254 | GRUBECK-LOEBENSTEIN, et al., "Immunization with β -amyloid: could T-cell activation have a harmful effect?", <u>TINS</u> , 23:114 (2000). |
| 117 | GUPTA et al., "Differences in the immunogenicity of native and formalized cross reacting material (CRM197) of diphtheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs," <u>Vaccine</u> , 15(12/13): 1341-1343 (1997). |
| 241 | HAASS et al., "Amyloid beta-peptide is produced by cultured cells during normal metabolism," <u>Nature</u> , 359(6393):322-326 (1992). |
| 487 | HAASS et al., "Protofibrils, the unifying toxic molecule of neurodegenerative disorders?", <u>Nature Neuroscience</u> , 4(9):859-860 (2001). |

| | | | |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | <i>Cheng</i> | Date Considered | 09/15/2005 |
|--------------------|--------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60475801 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|----|--------------------------|-----------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/823,453 |
| | | Filing Date | April 12, 2004 |
| | | First Named Inventor | Schenk, D. B. |
| | | Art Unit | 1647 |
| | | Examiner Name | Nichols, C. J. |
| | | Attorney Docket Number | 16270J-004754US |
| Sheet | 16 | of | 31 |

| | | | |
|-----|-----|---|--|
| Cyp | 118 | HAGA et al., "Synthetic Alzheimer amyloid β /A4 peptides enhance production of complement C3 component by cultured microglial cells." <u>Brain Research</u> , 801:88-94 (1993). | |
| | 182 | HANAN and SOLOMON, "Inhibitory effect of monoclonal antibodies on Alzheimer's β -amyloid peptide aggregation," <u>Int. J. Exp. Clin. Invest.</u> , 3:130-133 (1996). | |
| | 119 | HANES et al., "New advances in microsphere-based single-dose vaccines," <u>Advanced Drug Delivery Reviews</u> , 28: 87-119 (1997). | |
| | 120 | HARDY, "Amyloid, the presenilins and Alzheimer's disease," <u>TINS</u> , 20(4): 154-159 (1997). | |
| | 121 | HARDY, John, "New Insights into the Genetics of Alzheimer's Disease," <u>Annals of Med.</u> , 28:255-258 (1998). | |
| | 255 | HARIGAYA, et al., "Modified amyloid β protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease," <u>Biochem. Biophys. Res. Comm.</u> , 211:1015-1022 (1995). | |
| | 193 | HARRINGTON et al., "Characterization of an epitope specific to the neuron-specific isoform of human enolase recognized by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of β / A4-protein," <u>Biochimica Biophysica Acta</u> , 1158:120-128 (1993). | |
| | 229 | HAZAMA, et al., "Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of Escherichia Coli Heat-Labile Enterotoxin and Interleukin-2," <u>Immunology</u> , 78:643-649 (1993). | |
| | 476 | HE et al., "Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P- selectin," <u>J. Immunol.</u> , 160:1029-1035 (1998). | |
| | 177 | HELMUTH, "Further Progress on a β -Amyloid Vaccine," <u>Science</u> , 289:375 (2000). | |
| | 559 | HERLYN et al., "Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma," <u>Eur. J. Immunol.</u> , 9:657-659 (1979). | |
| | 473 | HILBICH et al., "Aggregation and secondary structure of synthetic amyloid β A4 peptides of Alzheimer's disease," <u>J. Mol. Biol.</u> , 218:149-163 (1991). | |
| | 471 | HILBICH et al., "Substitutions of hydrophobic amino acid reduce the amyloidogenicity of Alzheimer's disease β A4 peptides" <u>J. Mol. Biol.</u> , 228:460-473 (1992). | |
| | 236 | HILBICH et al., "Human and rodent sequence analogs of Alzheimer's amyloid β A4 share similar properties and can be solubilized in buffers of pH 7.4," <u>Eur. J. Biochem.</u> , 201:61-69 (1991). | |
| Cyp | 534 | HOCK et al., "Antibodies against β -Amyloid Slow Cognitive Decline in Alzheimer's Disease," <u>Neuron</u> , 38:542-554 (2003). | |

| | | | |
|--------------------|--|-----------------|------------|
| Examiner Signature | | Date Considered | 09/15/2005 |
|--------------------|--|-----------------|------------|

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231, 60475801 v1

PTO/S&O88 (10-01)

Approved for use through 10/31/2002, OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|------------------------|--------------------------|----------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/823,463 |
| | | Filing Date | April 12, 2004 |
| | | First Named Inventor | Schenk, D. B. |
| | | Art Unit | 1647 |
| | | Examiner Name | Nichols, C. J. |
| Sheet 17 of 31 | Attorney Docket Number | 15270J-004734US | |

| | |
|-----|--|
| 413 | HOLTZMAN et al., "A β immunization and anti-A β antibodies: potential therapies for the prevention and treatment of Alzheimer's disease," <u>Advanced Drug Delivery Reviews</u> , 54:1603-1613 (2002). |
| 122 | HSIAO et al., "Correlative Memory Deficits, A β Elevation, and Amyloid Plaques in Transgenic Mice," <u>Science</u> , 274: 99-102 (1995). |
| 123 | HUBERMAN et al., "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," <u>J. Neuroimmunology</u> , 52:147-152 (1994). |
| 174 | Human Immunology & Cancer Program brochure, from The University of Tennessee Medical Center/ Graduate School of Medicine, Knoxville, Tennessee (publication date unknown). |
| 124 | HYMAN et al., "Molecular Epidemiology of Alzheimer's Disease," <u>N. E. J. Medicine</u> , 333(19):1283-1284 (1995). |
| 256 | IKEDA, et al., "Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti- β protein monoclonal antibody," <u>Lab. Invest.</u> , 57:446-449 (1987). |
| 548 | IRIZARRY et al., "A β Deposition Is Associated with Neuropil Changes, but not with Overt Neuronal Loss in the Human Amyloid Precursor Protein V717F (PDAPP) Transgenic Mouse," <u>J. Neuroscience</u> , 17(18):7053-7059 (1997). |
| 125 | ITAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," <u>J. Neuroimmunology</u> , 24:173-182 (1989). |
| 192 | IWATSUBO et al., "Visualization of A β 42(43) and A β 40 in Senile Plaques with End-Specific A β Monoclonals: Evidence That an Initially Deposited Species Is A β 42(43)," <u>Neuron</u> , 13:45-53 (1994). |
| 560 | JÄHRLING et al., "Opsonization of Alphaviruses in Hamsters," <u>J. Medical Virology</u> , 12:1-16 (1983). |
| 374 | JAKES et al., "Characterisation of an Antibody Relevant to the Neuropathology of Alzheimer Disease," <u>Alzheimer Disease and Associated Disorders</u> , 9(1):47-51 (1995). |
| 126 | JANSEN et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," <u>Immun. Rev.</u> , 62: 185-216 (1982). |
| 308 | JANUS et al., "A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease," <u>Nature</u> , 408(6815):979-982 (2000). |
| 257 | JEN, et al., "Preparation and purification of antisera against different regions or isoforms of b-amyloid precursor protein," <u>Brain Research Protocols</u> , 2:23-30 (1997). |

| | | | |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | <i>Chang</i> | Date Considered | 09/15/2005 |
|--------------------|--------------|-----------------|------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60475801 v1

PTO/SB/028 (10-01)

Approved for use through 10/31/2002. OMB 0631-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|----|--------------------------|-----------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/823,463 |
| | | Filing Date | April 12, 2004 |
| | | First Named Inventor | Schenk, D. B. |
| | | Art Unit | 1847 |
| | | Examiner Name | Nichols, C. J. |
| | | Attorney Docket Number | 15270J-004754US |
| Sheet | 18 | of | 31 |

| | | |
|-----|-----|--|
| CyW | 218 | JOACHIM et al., "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," <u>Am. J. of Pathology</u> , 138:373-384 (1991). |
| | 334 | JOBLING et al., "Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis," <u>Molecular Microbiology</u> , 5(7):1755-1767 (1991). |
| | 449 | JOHNSON-WOOD et al., "Amyloid precursor protein processing and A β_{42} deposition in a transgenic mouse model of Alzheimer disease," <u>PNAS</u> , 94:1550-1555 (1997). |
| | 371 | JOHNSTONE et al., Nuclear and Cytoplasmic Localization of the β -Amyloid Peptide (1-43) in Transfected 293 Cells," <u>Biochem. Biophys. Res. Comm.</u> , 220:710-718 (1996). |
| | 347 | JORBECK et al., "Artificial <i>Salmonella</i> Vaccines: <i>Salmonella typhimurium</i> O-antigen-Specific Oligosaccharide-Protein Conjugates Elicit Opsonizing Antibodies that Enhance Phagocytosis," <u>Infection and Immunity</u> , 32(2):497-502 (1981). |
| | 127 | KALARIA, R. N., "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," <u>Res. Immunology</u> , 143:637-641 (1992). |
| | 183 | KATZAV-GOZANSKY et al., "Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation," <u>Biotechnol. Appl. Biochem.</u> , 23:227-230 (1996). |
| | 128 | KAWABATA et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," <u>Nature</u> , 354:476-478 (1991). |
| | 547 | KAYED et al., "Conformational Transitions of Islet Amyloid Polypeptide (IAPP) in Amyloid Formation <i>In Vitro</i> ," <u>J. Mol. Biol.</u> , 287:781-796 (1999). |
| | 434 | KELLY, J. W., "Alternative conformations of amyloidogenic proteins govern their behavior," <u>Current Opinion in Structural Biology</u> , 6:11-17 (1996). |
| | 554 | KETTLEBOROUGH et al., "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation," <u>Protein Engineering</u> , 4(7):773-783 (1991). |
| | 258 | KIDA, et al., "Early amyloid- β deposits show different immunoreactivity to the amino- and carboxy-terminal regions of b-peptide in Alzheimer's disease and Down's syndrome brain," <u>Neuroscience Letters</u> , 193:105-108 (1995). |
| | 488 | KLEIN et al., "Targeting small A β oligomers: the solution to an Alzheimer's disease conundrum?," <u>Trends in Neurosciences</u> , 24(4):219-224 (2001). |
| CyW | 195 | KONIG et al., "Development and Characterization of a Monoclonal Antibody 369.2B Specific for the Carboxyl-Terminus of the A β 4 Peptide," <u>Annals of NY Acad. Sci.</u> , 777:344-355 (1996). |

| | | | |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | <i>Chang</i> | Date Considered | 09/15/2005 |
|--------------------|--------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60475801 v1

PTO/SB/05B (10-01)

Approved for use through 10/31/2002. OMB 0451-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|----|--------------------------|-----------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/823,463 |
| | | Filing Date | April 12, 2004 |
| | | First Named Inventor | Schenk, D. B. |
| | | Art Unit | 1647 |
| | | Examiner Name | Nichols, C. J. |
| | | Attorney Docket Number | 15270J-004754US |
| Sheet | 19 | of | 31 |

| | | | |
|-----|-----|--|--|
| Cyw | 494 | KOTILINEK et al., "Reversible memory loss in a mouse transgenic model of Alzheimer's disease," <u>J. Neurosci.</u> , 22(15):6331-6335 (2002). | |
| | 466 | KOUDINOV et al., "The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma," <u>Biochem. & Biophys. Res. Comm.</u> , 205:1164-1171 (1994). | |
| | 389 | KOVACS et al., "Mutations of the Prion Protein Gene Phenotypic Spectrum," <u>J. Neurol.</u> , 249:1587-1592 (2002). | |
| | 478 | KUO et al., "High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease," <u>Biochem. Biophys. Res. Comm.</u> , 257(3):787-791 (1999). | |
| | 477 | LAMBERT et al., "Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins," <u>PNAS</u> , 95:6448-6453 (1998). | |
| | 489 | LAMBERT et al., "Vaccination with soluble Aβ oligomers generates toxicity-neutralizing antibodies," <u>J. Neurochem.</u> , 79:595-605 (2001). | |
| | 129 | LAMPERT-ETCHELLS et al., "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," <u>Neurodegeneration</u> , 2:111-121 (1993). | |
| | 130 | LANGER, "New Methods of Drug Delivery," <u>Science</u> , 249:1527-1532 (1990). | |
| | 131 | LANNFELT et al., "Alzheimer's disease: molecular genetics and transgenic animal models," <u>Behavioural Brain Res.</u> , 57:207-213 (1993). | |
| | 269 | LANSBURY, PETER T., "Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease," <u>Curr. Ops. in Chemical Biology</u> , 1:260-267 (1997). | |
| | 490 | LEE et al., "Aβ Immunization: Moving Aβ peptide from brain to blood," <u>PNAS</u> , 98(16):8931-8932 (2001). | |
| | 132 | LEMERE et al., "Mucosal Administration of Aβ Peptide Decreases Cerebral Amyloid Burden in Pd-App Transgenic Mice," <u>Society for Neuroscience Abstracts</u> , 25(part 1), Abstract 519.6, 29th Annual Meeting, (October 23-28, 1999). | |
| | 260 | LEMERE, et al., "Nasal Aβ treatment induces anti-Aβ antibody production and decreases cerebral amyloid burden in PD-APP mice," <u>Annals of the NY Acad. Sci.</u> , 920:328-331 (2000). | |
| | 553 | LEMERE et al., "Intranasal Immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants," <u>Neurobiology of Aging</u> , 23(6):991-1000 (2002). | |
| | 551 | LEVERONE et al., "Aβ1-15 is less immunogenic than Aβ1-40/42 for intranasal immunization of wild-type mice but may be effective for boosting," <u>Vaccine</u> , 21:2197-2206 (2003). | |
| Cyw | 459 | LEVITT, M., "Molecular dynamics of native protein," <u>J. Mol. Biol.</u> , 168:595-620 (1983). | |

| | | | |
|--------------------|----------------------|-----------------|------------|
| Examiner Signature | <i>Chang S. Yang</i> | Date Considered | 09/15/2005 |
|--------------------|----------------------|-----------------|------------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231, 60475801 v1

PTO/SB-018 (10-01)

Approved for use through 10/31/2002. OMB 0651-0001
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|----|--------------------------|-----------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/823,463 |
| | | Filing Date | April 12, 2004 |
| | | First Named Inventor | Schenk, D. B. |
| | | Art Unit | 1847 |
| | | Examiner Name | Nichols, C. J. |
| | | Attorney Docket Number | 15270J-004754US |
| Sheet | 20 | of | 31 |

| | | | |
|------|-----|---|--|
| Cyru | 481 | LEVY et al., "Immunization for Alzheimer's disease: A shot in the arm or a whiff?", <u>American Neurological Assoc.</u> 48:553-554 (2000). | |
| | 184 | U et al., "Thermal Stabilization of Carboxypeptidase A as a Function of PH and Ionic Milieu," <u>Biochem. Mol. Biol. Int.</u> 43(3):601-611 (1997). | |
| | 133 | LIVINGSTON et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection," <u>J. Immunol.</u> 159:1383-1392 (1997). | |
| | 134 | LOPEZ et al., "Serum auto-antibodies in Alzheimer's disease," <u>Acta. Neurol. Scand.</u> 84:441-444 (1991). | |
| | 499 | LUE et al., "Soluble β -amyloid Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease," <u>Am. J. Pathol.</u> 155:653-662 (1999). | |
| | 502 | MAGGIO et al., "Brain Amyloid - A Physicochemical Perspective," <u>Brain Pathology</u> 6:147-162 (1996). | |
| | 218 | MAJOCHA et al., "Development of a Monoclonal Antibody Specific for β /A4 Amyloid in Alzheimer's Disease Brain for Application to In Vitro Imaging of Amyloid Angiopathy," <u>The J. of Nuclear Med.</u> 33:2184-2189 (1992). | |
| | 261 | MAK, et al., "Polyclonals to β -amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum," <u>Brain Research</u> 667:138-142 (1994). | |
| | 263 | MANN, et al., "Amyloid β protein (A β) deposition in chromosome 14-linked Alzheimer's disease: Predominance of A β _{42/43} ," <u>Annals of Neurology</u> 40:149-156 (1996). | |
| | 262 | MANN, et al., "The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype," <u>Neuroscience Letters</u> 198:105-108 (1995). | |
| | 408 | MARSHALL, E., "Gene Therapy's Growing Pains," <u>Science</u> , 269:1050-1055 (1995). | |
| | 335 | MASLIAH et al., " β -Amyloid peptides enhance α -synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease," <u>PNAS</u> 98(21):12245-12250 (2001). | |
| | 545 | MASLIAH et al., "Comparison of Neurodegenerative Pathology in Transgenic Mice Overexpressing V717F β -Amyloid Precursor Protein and Alzheimer's Disease," <u>J. Neuroscience</u> 18(18):5795-5811 (1998). | |
| Cyru | 217 | MASTERS et al., "Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome," <u>PNAS</u> 82:4245-4249 (1985). | |

| | | | |
|--------------------|-------------------|-----------------|------------|
| Examiner Signature | <i>Changsheng</i> | Date Considered | 09/15/2005 |
|--------------------|-------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60475801 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|------------------------|--------------------------|----------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/823,463 |
| | | Filing Date | April 12, 2004 |
| | | First Named Inventor | Schenk, D. B. |
| | | Art Unit | 1847 |
| | | Examiner Name | Nichols, C. J. |
| Sheet 21 of 31 | Attorney Docket Number | 15270J-004754US | |

| | | | |
|-----|-----|--|--|
| Cyw | 309 | MATTSON, "Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives," <u>Physiol Rev.</u> , 77(4):1081-132 (1997). | |
| | 135 | MCGEE et al., "The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility," <u>J. Micro. Encap.</u> , 14(2):197-210 (1997). | |
| | 284 | MCGEER et al., "Immunohistochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy," <u>J. of Neuroscience Res.</u> , 31:428-442 (1992). | |
| | 479 | MCLEAN et al., "Soluble pool of A β amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease," <u>Amer. Neurological Assoc.</u> , 46:860-866 (1999). | |
| | 238 | MCNEAL et al., "Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21," <u>Virology</u> , 243:158-188 (1998). | |
| | 136 | MEDA et al., "Activation of microglial cells by β -amyloid protein and interferon- γ ," <u>Nature</u> , 374:647-650 (1995). | |
| | 265 | MENA, et al., "Monitoring pathological assembly of tau and β -amyloid proteins in Alzheimer's disease," <u>Acta Neuropathol.</u> , 89:50-58 (1995). | |
| | 310 | MERLUZZI, et al., "Humanized antibodies as potential drugs for therapeutic use," <u>Adv Clin Path.</u> , 4(2):77-85 (2000). | |
| | 137 | MILLER et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," <u>J. Exp. Med.</u> , 174:791-798 (1991). | |
| | 367 | MONSONEGO et al., "Immune hyporesponsiveness to amyloid β -peptide in amyloid precursor protein transgenic mice: Implications for the pathogenesis and treatment of Alzheimer's disease," <u>PNAS</u> , 98(18):10273-10278 (2001). | |
| | 311 | MORGAN, et al., "A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease," <u>Nature</u> , 408(6815):982-985 (2000). | |
| | 206 | MORI et al., "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," <u>J. Biol. Chem.</u> , 267(24):17082-17088 (1992). | |
| | 233 | MORRIS, et al., "The Consortium to Establish a registry for Alzheimer's Disease (CERAD)," <u>Neurology</u> , 39:1159-1165 (1989). | |
| Cyw | 359 | MUNCH et al., "Potential neurotoxic inflammatory response to A β vaccination in humans," <u>J. Neural Transm.</u> , 109:1081-1087 (2002). | |

| | | | |
|--------------------|-----------------|-----------------|-----------|
| Examiner Signature | <i>Chang-yu</i> | Date Considered | 9/15/2005 |
|--------------------|-----------------|-----------------|-----------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60473801 v1

PTO/SB/038 (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|----|--------------------------|-----------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/823,463 |
| | | Filing Date | April 12, 2004 |
| | | First Named Inventor | Schenk, D. B. |
| | | Art Unit | 1647 |
| | | Examiner Name | Nichols, C. J. |
| | | Attorney Docket Number | 15270J-004754US |
| Sheet | 22 | of | 31 |

| | | | |
|----|-----|---|--|
| Cy | 355 | MUNSON eds., <i>Principals of Pharmacology: Basic Concepts & Clinical Applications</i> , pgs. 47-48, Chapman & Hall, New York, New York (1996). | |
| | 191 | MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β -Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," <i>Am. J. Pathology</i> , 144(5):1082-1088 (1994). | |
| | 354 | MUTSCHLER et al., <i>Drug Actions: Basic Principles and Therapeutic Aspects</i> pgs. 7, 11-12, Medpharm Scientific Publishers, Stuttgart, Germany (1995). | |
| | 250 | NAKAMURA et al., "Histopathological studies on senile plaques and cerebral amyloid angiopathy in aged cynomolgus monkeys," <i>Exp. Anim.</i> , 43:711-718 (1995). | |
| | 268 | NAKAMURA, et al., "Carboxyl end-specific monoclonal antibodies to amyloid β protein (A β) subtypes (A β 40 and A β 42(43) differentiate Ab in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys," <i>Neuroscience Letters</i> , 201:151-154 (1995). | |
| | 281 | NAKAYAMA et al., "Histopathological studies of senile plaques and cerebral amyloidosis in cynomolgus monkeys," <i>J. of Med. Primatology</i> , 27:244-252 (1998). | |
| | 439 | NALBANTOGLU, J., "Beta-amyloid protein in Alzheimer's disease," <i>Can. J. Neurol. Sci.</i> , 18(3 suppl):424-427 (1991), abstract only | |
| | 482 | NASLUND et al., "Correlation between elevated levels of amyloid β peptide in the brain and cognitive decline," <i>J. Am. Med. Assoc.</i> , 283:1571 (2000). | |
| | 138 | NATHANSON et al., "Bovine Spongiform Encephalopathy (BSE): Causes and Consequences of a Common Source Epidemic," <i>Am. J. Epidemiol.</i> , 145(11):959-969 (1997). | |
| | 139 | New York Times National, "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94). | |
| | 235 | NEWCOMBE et al., "Solubility characteristics of isolated amyloid fibrils," <i>Biochim. Biophys. Acta</i> , 104:480-486 (1985). | |
| | 425 | NGO et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," pages 492-495 from Chapter 14 of <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , Merz et al., eds., Birkhauser Boston (1994). | |
| | 350 | NICOLL et al., "Neuropathology of human Alzheimer's disease after immunization with amyloid- β peptide: a case report," <i>Nature Medicine</i> , 9(4):448-452 (2003). | |
| Cy | 329 | NIEMANN, "Transgenic farm animals get off the ground," <i>Transgenic Research</i> , 7:73-75 (1998). | |

| | | | |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | <i>Chang</i> | Date Considered | 09/15/2005 |
|--------------------|--------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60475801 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|--|------------------------|--------------------------|----------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT. (use as many sheets as necessary) | | Application Number | 10/823,463 |
| | | Filing Date | April 12, 2004 |
| | | First Named Inventor | Schenk, D. B. |
| | | Art Unit | 1647 |
| | | Examiner Name | Nichols, C. J. |
| Sheet 23 of 31 | Attorney Docket Number | 16270J-004754US | |

| | | | |
|-----|-----|---|--|
| CyW | 568 | NOVOTNY et al., "Structural invariants of antigen binding: Comparison of immunoglobulin V _L -V _H and V _L -V _L domain dimers," <u>PNAS</u> , 82:4592-4596 (1985). | |
| | 409 | ORKIN et al., <i>Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy</i> , December 7, 1995 | |
| | 398 | PALHA et al., "Antibody recognition of amyloidogenic transthyretin variants in serum of patients with familial amyloidotic polyneuropathy," <u>J. Mol. Med.</u> , 7:703-707 (2001). | |
| | 406 | PAN et al., "Antibodies to β -Amyloid Decrease the Blood-to-Brain Transfer of β -Amyloid Peptide," <u>Exp. Biol. Med.</u> , 227(8):809-815 (2002). | |
| | 280 | PARDRIDGE et al., "Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier," <u>Biochem. Biophys. Res. Comm.</u> , 146:307-313 (1987). | |
| | 140 | PARESCIE et al., "Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor," <u>Neuron</u> , 17:553-565 (September 1996). | |
| | 141 | PAUL et al., "Transdermal immunization with large proteins by means of ultradeformable drug carriers," <u>Eur. J. Immunol.</u> , 25: 3521-3524 (1995). | |
| | 564 | PCT Search Report of 12/14/04 for application PCT/US04/02856 | |
| | 437 | PERSSON et al., "IgG subclass-associated affinity differences of specific antibodies in humans," <u>J. Immunology</u> , 140(11):3875-3879 (1988), abstract only | |
| | 336 | PERUTZ et al., "Amyloid fibers are water-filled nanotubes," <u>PNAS</u> , 99(8):5591-5595 (2002). | |
| | 232 | PETERSON, et al., "Recombinant Antibodies: Alternative Strategies for Developing and Manipulating Murine-Derived Monoclonal Antibodies," <u>Laboratory Animal Science</u> , 46(1):8-14 (1996). | |
| | 289 | PHILIPPE, et al. "Generation of a monoclonal antibody to the carboxy-terminal domain of tau by immunization with the amino-terminal domain of the amyloid precursor protein," <u>J. of Neuroscience Res.</u> , 46:709-719 (1996). | |
| | 491 | PODUSLO et al., "Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease," <u>Neurobiol. Dis.</u> , 8(4):555-567 (2001). | |
| | 142 | PRIEELS et al., "Synergistic adjuvants for vaccines," <u>Chemical Abstracts</u> , 120(8):662, column 1, abstract 86406t (1994). | |
| CyW | 394 | PRUSINER et al., "Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies," <u>PNAS</u> , 90:10808-10812 (1993). | |

| | | | |
|--------------------|-------------------|-----------------|------------|
| Examiner Signature | <i>Chang-feng</i> | Date Considered | 09/15/2005 |
|--------------------|-------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231, 60475801 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|----|--------------------------|-----------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/823,483 |
| | | Filing Date | April 12, 2004 |
| | | First Named Inventor | Schenk, D. B. |
| | | Art Unit | 1847 |
| | | Examiner Name | Nichols, C. J. |
| | | Attorney Docket Number | 15270J-004754US |
| Sheet | 24 | of | 31 |

| | | | |
|-----|-----|--|--|
| CyW | 460 | QUEEN et al., "A humanized antibody that binds to the Interleukin 2 receptor," <u>PNAS</u> , 86:10029-10033 (1989). | |
| | 143 | QUON et al., "Formation of β -Amyloid protein deposits in brains of transgenic mice," <u>Nature</u> , 352:239-241 (1991). | |
| | 497 | RAGUSI et al., "Redistribution of Imipramine from Regions of the Brain Under the Influence of Circulating Specific Antibodies," <u>J. Neurochem.</u> , 70(5):2099-2105 (1998). | |
| | 145 | RASO, "Immunotherapy of Alzheimer's Disease," <u>Immunotherapy Weekly</u> , Abstract (April 2, 1998). | |
| | 304 | RASO, V.A., Grant application # 1 R43 AG1 5748-01 (non-redacted version), "Immunotherapy of Alzheimer's Disease" (publication date unknown). | |
| | 144 | RASO, V.A., Grant application # 1 R43 AG1 5748-01 (redacted version), "Immunotherapy of Alzheimer's Disease" (publication date unknown). | |
| | 146 | ROGERS et al., "Complement activation by β -amyloid in Alzheimer Disease," <u>PNAS</u> , 89:1-5 (1992). | |
| | 147 | ROSSOR et al., "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," <u>Annals of New York Academy of Sciences</u> , 695:198-202 (1993). | |
| | 209 | RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in <u>Peptide Hormones</u> , J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1976). | |
| | 189 | SAIDO et al., "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," <u>J. Biol. Chem.</u> , 268(33):25239-25243 (1993). | |
| | 194 | SAIDO et al., "Spatial Resolution of the Primary β -Amyloidogenic Process Induced in Postischemic Hippocampus," <u>J. Biol. Chem.</u> , 269(21):15253-15257 (1994). | |
| | 279 | SAITO et al., "Vector-mediated delivery of 125 I-labeled β -amyloid peptide Ab $^{1-40}$ through the blood-brain barrier and binding to Alzheimer disease amyloid of the A β^{1-40} vector complex," <u>PNAS</u> , 92:10227-10231 (1995). | |
| | 278 | SAITOH, N. et al., "Immunological analysis of Alzheimer's disease using anti- β -protein monoclonal antibodies," <u>Seppore Med. J.</u> , 60:309-320 (1991). | |
| | 277 | SASAKI et al., "Human choroid plexus is an uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study," <u>Brain Res.</u> , 755:193-201 (1997). | |
| CyW | 148 | SCHENK et al., "Immunization with amyloid- β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," <u>Nature</u> , 400:173-177 (1999). | |

| | | | |
|--------------------|--|-----------------|------------|
| Examiner Signature | | Date Considered | 09/15/2005 |
|--------------------|--|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 909. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60475801 v1

PTO/SB/038 (10-01)

Approved for use through 10/31/2002. CMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|----|--------------------------|-----------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/823,483 |
| | | Filing Date | April 12, 2004 |
| | | First Named Inventor | Schenk, D. B. |
| | | Art Unit | 1647 |
| | | Examiner Name | Nichols, C. J. |
| | | Attorney Docket Number | 15270J-004754US |
| Sheet | 25 | of | 31 |

| | |
|-----|---|
| 178 | SCHENK et al., "Therapeutic Approaches Related to Amyloid- β Peptide and Alzheimer's Disease," <u>J. Med. Chem.</u> , 38(21):4141-4154 (1995). |
| 270 | SCHENK et al., " β -peptide immunization," <u>Arch. Neurol.</u> , 57:934-936 (2000). |
| 312 | SCHENK et al., "Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier," <u>DNA Cell Biol.</u> , 20(11):679-81 (2001). |
| 414 | SCHENK, D., "Amyloid- β immunotherapy for Alzheimer's disease: the end of the beginning," <u>Nature Reviews</u> , 3:824-828 (2002). |
| 466 | SCHWARZMAN et al., "Transferrin sequesters amyloid β protein and prevents amyloid formation," <u>PNAS</u> , 91:8368-8372 (1994). |
| 536 | SELA et al., "Different roles of D-amino acids in immune phenomena," <u>FASEB J.</u> , 11(6):449-456 (1999). |
| 150 | SELKOE, "Alzheimer's Disease: A Central Role for Amyloid," <u>J. Neuropathol. Exp. Neurol.</u> , 53(5): 438-447 (1994). |
| 151 | SELKOE, "Physiological production of the β -amyloid protein and the mechanism of Alzheimer's disease," <u>Trends in Neurosciences</u> , 16(10): 403-409 (1993). |
| 313 | SELKOE, "The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease," <u>Trends Cell Biol.</u> , 8(11):447-53 (1998). |
| 149 | SELKOE, D.J., "Imaging Alzheimer's Amyloid," <u>Nat. Biotech.</u> , 18:823-824 (2000). |
| 155 | SELKOE, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," <u>Science</u> , 275:630-631 (1997). |
| 152 | SELKOE, Dennis J., "Amyloid Protein and Alzheimer's Disease.....," <u>Scientific American</u> , pgs. 68-78 (1991). |
| 153 | SELKOE, Dennis J., "In the Beginning...." <u>Nature</u> , 354:432-433 (1991). |
| 154 | SELKOE, Dennis J., "The Molecular pathology of Alzheimer's Disease," <u>Neuron</u> , 6:487-498 (1991). |
| 156 | SEUBERT et al., "Isolation and quantification of soluble Alzheimer's β -peptide from biological fluids," <u>Nature</u> , 359: 325-327 (1992). |
| 157 | SHIOSAKA, S., "Attempts to make models for Alzheimer's disease," <u>Neuroscience Res.</u> , 13:237-255 (1992). |

| | | | |
|--------------------|--|-----------------|------------|
| Examiner Signature | | Date Considered | 09/15/2005 |
|--------------------|--|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60475801 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0091

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|------------------------|--------------------------|----------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/823,463 |
| | | Filing Date | April 12, 2004 |
| | | First Named Inventor | Schenk, D. B. |
| | | Art Unit | 1847 |
| | | Examiner Name | Nichols, C. J. |
| Sheet 26 of 31 | Attorney Docket Number | 15270J-004754US | |

| | | | |
|-----|-----|--|--|
| CyW | 330 | SIGMUND, "Viewpoint: Are Studies In Genetically Altered Mice Out of Control," <u>Arterioscler Thromb Vasc Biol.</u> , 20:1425-1429 (2000). | |
| | 400 | SIGURDSSON et al., "A safer vaccine for Alzheimer's disease?," <u>Neurobiology of Aging</u> , 23:1001-1008 (2002). | |
| | 398 | SIGURDSSON et al., "Anti-prion antibodies for prophylaxis following prion exposure in mice," <u>Neuroscience Letters</u> , 336:185-187 (2003). | |
| | 384 | SIGURDSSON et al., "Immunization Delays the Onset of Prion Disease in Mice," <u>American Journal of Pathology</u> , 161:13-17 (2002). | |
| | 314 | SIGURDSSON, et al., "In vivo reversal of amyloid-beta lesions in rat brain," <u>J Neuropathol Exp Neurol</u> , 59(1):11-17 (2000). | |
| | 552 | SIGURDSSON et al., "Immunization with a Nontoxic/Nonfibrillar Amyloid- β Homologous Peptide Reduces Alzheimer's Disease-Associated Pathology in Transgenic Mice," <u>Am. J. Pathology</u> , 159(2):439-447 (2001). | |
| | 505 | SIMMONS, L., "Secondary structure of amyloid β peptide correlates with neurotoxic activity <i>in vitro</i> ," <u>Molecular Pharmacology</u> , 45:373-379 (1994). | |
| | 428 | SINGH, K. S., "Neuroautoimmunity: Pathogenic Implications for Alzheimer's Disease," <u>Gerontology</u> , 43:79-94 (1997). | |
| | 438 | SINGH, V. K., "Studies of neuroimmune markers in Alzheimer's disease," <u>Mol. Neurobiology</u> , 9(1-3):73-81 (1994), abstract only | |
| | 315 | SINHA, et al., "Recent advances in the understanding of the processing of APP to beta amyloid peptide," <u>Ann N Y Acad Sci</u> , 920:206-8 (2000). | |
| | 368 | SIPE, "Amyloidosis," <u>Annu. Rev. Biochem.</u> , 61:947-975 (1992). | |
| | 337 | SKOLNICK and FETROW, "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <u>Trends in Biotech.</u> , 18(1):34-39 (2000). | |
| | 319 | SMALL et al., "Alzheimer's disease and Abeta toxicity: from top to bottom," <u>Nat Rev Neurosci.</u> , 2(8):595-8 (2001). | |
| | 427 | SMITH et al., "The challenges of genome sequence annotation or 'The devil is in the details,'" <u>Nature Biotechnology</u> , 15:1222-1223 (1997). | |
| CyW | 158 | SMITS et al., "Prion Protein and Scrapie Susceptibility," <u>Vel. Quart.</u> , 19(3):101-105 (1997). | |

| | | | |
|--------------------|--------------|-----------------|-----------|
| Examiner Signature | <i>Chang</i> | Date Considered | 0 9/15/05 |
|--------------------|--------------|-----------------|-----------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60475801 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|----|--------------------------|-----------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/823,483 |
| | | Filing Date | April 12, 2004 |
| | | First Named Inventor | Schenk, D. B. |
| | | Art Unit | 1647 |
| | | Examiner Name | Nichols, C. J. |
| | | Attorney Docket Number | 15270J-004754US |
| Sheet | 27 | of | 31 |

| | | | |
|----|-----|--|--|
| Cy | 185 | SOLOMON and et al., "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyvinyl Alcohols," <u>Adv. Mol. Cell Biology</u> , 15A:33-45 (1996). | |
| | 186 | SOLOMON et al., "Activity of monoclonal antibodies in prevention of in vitro aggregation of their antigens," abstract from Department of Molecular Microbiology and Biotechnology, Tel Aviv University, Tel Aviv, Israel (publication date unknown). | |
| | 159 | SOLOMON et al., "Disaggregation of Alzheimer β -amyloid by site-directed mAb," <u>PNAS</u> , 94:4109-4112 (1997). | |
| | 160 | SOLOMON et al., "Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β -amyloid peptide," <u>PNAS</u> , 93:452-455 (1996). | |
| | 411 | SOLOMON et al., "The Amino Terminus of the β -Amyloid Peptide Contains an Essential Epitope for Maintaining Its Solubility," from <u>Progress in Alzheimer's and Parkinson's Diseases</u> , edited by Fisher et al., Plenum Press, New York, pages 205-211 (1995). | |
| | 161 | SOLOMON, A., "Pro-Fx (Protein Therapeutics)," University of Tennessee Medical Center (publication date unknown). | |
| | 162 | SOLOMON, B., "New Approach Towards Fast Induction of Anti β -Amyloid Peptide Immune Response," Department of Molecular Microbiology & Biotechnology, Tel-Aviv University, Ramat Aviv, Tel-Aviv, Israel (publication date unknown). | |
| | 549 | SOLOMON, B., "Immunological approaches as therapy for Alzheimer's disease," <u>Expert Opin. Biol. Ther.</u> , 2(8):907-917 (2002). | |
| | 316 | SOTO et al., "Beta sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy," <u>Nature Medicine</u> , 4(7):822-826 (1998). | |
| | 508 | SOTO et al., "The α -helical to β -strand transition in the amino-terminal fragment of the amyloid β -peptide modulates amyloid formation," <u>J. Biol. Chem.</u> , 270(7):3063-3067 (1995). | |
| | 179 | SOUTHWICK et al., "Assessment of Amyloid β protein in Cerebrospinal fluid as an Aid in the Diagnosis of Alzheimer's Disease," <u>J. Neurochemistry</u> , 66:259-265 (1996). | |
| | 389 | SPOONER et al., "The generation and characterization of potentially therapeutic A β antibodies in mice: differences according to strain and immunization protocol," <u>Vaccine</u> , 21:290-297 (2002). | |
| | 271 | ST. GEORGE-HYSLOP et al., "Antibody clears senile plaques," <u>Nature</u> , 40:116-117 (1999). | |
| Cy | 338 | STEIN et al., "Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein is Associated with Increased Levels of Transferrin and Activation of Cell Survival Pathways," <u>The Journal of Neuroscience</u> , 22(17):7380-7388 (2002). | |

| | | | |
|--------------------|----------------|-----------------|------------|
| Examiner Signature | <i>Charles</i> | Date Considered | 09/15/2005 |
|--------------------|----------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60473801 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|----|--------------------------|-----------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/823,463 |
| | | Filing Date | April 12, 2004 |
| | | First Named Inventor | Schenk, D. B. |
| | | Art Unit | 1647 |
| | | Examiner Name | Nichols, C. J. |
| | | Attorney Docket Number | 15270J-004754US |
| Sheet | 28 | of | 31 |

| | | | |
|----|-----|---|--|
| Cy | 435 | STERN et al., "Antibodies to the β -amyloid peptide cross-react with conformational epitopes in human fibrinogen subunits from peripheral blood," <u>FEBS Letters</u> , 264(1):43-47 (1990). | |
| | 163 | STOUTE et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against <i>Plasmodium Falciparum</i> Malaria", <u>N. Engl. J. Med.</u> , 336(2):86-91 (1997). | |
| | 496 | STRBAK et al., "Passive Immunization and Hypothalamic Peptide Secretion", <u>Neuroendocrinology</u> , 58:210-217 (1993). | |
| | 164 | STURCHLER-PIERRAT et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," <u>PNAS</u> , 94: 13287-13292 (1997). | |
| | 381 | SU et al., "Intravascular Infusions of soluble β -amyloid compromise the blood-brain barrier, activate CNS Glial cells and induce peripheral hemorrhage," <u>Brain Research</u> , 818:105-107 (1999). | |
| | 498 | SUO et al., "Soluble Alzheimers β -amyloid constricts the cerebral vasculature in vivo" <u>Neuroscience Letters</u> , 257:77-80 (1998). | |
| | 272 | SZENDREI, et al., "The effects of aspartic acid-bond isomerization on in vitro properties of the amyloid β -peptide as modeled with N-terminal decapeptide fragments," <u>Int. J. Peptide Protein Res.</u> , 47:289-296 (1996). | |
| | 467 | TABATON et al., "Soluble amyloid β -protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid," <u>Biochem. and Biophys. Res. Comm.</u> , 200(3):1598-1603 (1994). | |
| | 392 | TAL et al., "Complete Freund's Adjuvant Immunization Prolongs Survival in Experimental Prion Disease in Mice," <u>Journal of Neuroscience Research</u> , 71:286-290 (2003). | |
| | 399 | TAN et al., "Amyloidosis," <u>Histopathology</u> , 25:403-414 (1994). | |
| | 166 | TANAKA et al., "NC-1900, an active fragment analog of arginine vasopressin, Improves learning and memory deficits induced by beta-amyloid protein in rats," <u>European J. Pharmacology</u> , 362:135-142 (1998). | |
| | 472 | TELLER et al., "Presence of soluble amyloid β -peptide precedes amyloid plaque formation in Down's syndrome" <u>Nature Medicine</u> , 2(1):93-95 (1996). | |
| | 339 | TENNENT et al., "Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis," <u>PNAS</u> , 92:4269-4303 (1995). | |
| | 273 | THORSETT, E.D. et al., "Therapeutic approaches to Alzheimer's disease," <u>Curr. Op. in Chem. Biology</u> , 4:377-382 (2000). | |
| Cy | 500 | TJERNBERG et al., "A molecular model for Alzheimer amyloid β -peptide fibril formation," <u>J. Biol. Chem.</u> , 274(18):12619-12625 (1999). | |

| | | | |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | <i>Chang</i> | Date Considered | 09/15/2005 |
|--------------------|--------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60475801 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|----|--------------------------|-----------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/823,483 |
| | | Filing Date | April 12, 2004 |
| | | First Named Inventor | Schenk, D. B. |
| | | Art Unit | 1847 |
| | | Examiner Name | Nichols, C. J. |
| | | Attorney Docket Number | 15270J-004754US |
| Sheet | 29 | of | 31 |

| | | |
|-----|-----|--|
| CyW | 276 | TJERNBERG et al., "Arrest of β -amyloid fibril formation by a pentapeptide ligand," <u>J. Biol. Chem.</u> , 271:8545-8548 (1996). |
| | 537 | TJERNBERG, et al, "Controlling amyloid beta-peptide fibril formation with protease-stable ligands," <u>J. Biol. Chem.</u> , 272(18):12601-12606 (1997). |
| | 492 | TOWN et al., "Characterization of murine immunoglobulin G antibodies against human amyloid- β_{1-42} " <u>Neurosci. Lett.</u> 307:101-104 (2001). |
| | 166 | TRIEB et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," <u>Immunobiology</u> , 191(2-3):114-115 Abstract C.37, (1994). |
| | 375 | TSUZUKI et al., "Amyloid β protein in rat soleus in chloroquine-induced myopathy using end-specific antibodies for A β 40 and A β 42: Immunohistochemical evidence for amyloid β protein," <u>Neuroscience Letters</u> , 2002:77-80 (1995). |
| | 167 | VAN GOOL et al., "Concentrations of amyloid- β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," <u>Neuroscience Letters</u> , 172:122-124 (1994). |
| | 535 | VAN REGENMORTEL et al., "D-peptides as immunogens and diagnostic reagents," <u>Curr. Opin. Biotechnol.</u> , 9(4):377-382 (1998). |
| | 317 | VEHMAS et al., "beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPsw/PS1 DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip® technology," <u>DNA Cell Biol.</u> , (11):713-721 (2001). |
| | 428 | VELAZQUEZ et al., "Aspartate residue 7 in amyloid β -protein is critical for classical complement pathway activation: Implications for Alzheimer's disease pathogenesis," <u>Nature Medicine</u> , 3(1):77-79 (1997). |
| | 168 | VERBEEK et al., "Accumulation of Interleukin Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," <u>Amer. Jour. Pathology</u> , 144(1):104-116 (1994). |
| | 410 | VERMA et al., "Gene therapy - promises, problems and prospects," <u>Nature</u> , 389:239-242 (1997). |
| | 589 | VERSHIGORA A. E. ODSHCAYA IMMUNOLOGIIYA, pages 35, 229-231 and 152-153. |
| | 189 | WALKER et al., "Labeling of Cerebral Amyloid In Vivo with a Monoclonal Antibody," <u>J. Neuropath. Exp. Neurol.</u> , 53(4):377-383 (1994). |
| | 480 | WANG et al., "The levels of soluble versus insoluble brain A β distinguish Alzheimer's disease from normal and pathologic aging," <u>Experimental Neurology</u> , 158:328-337 (1999). |
| CyW | 495 | WANG et al., "Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus," <u>Brain Research</u> , 924:133-140 (2002). |

| | | | |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | <i>Chang</i> | Date Considered | 09/15/2005 |
|--------------------|--------------|-----------------|------------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60475801 v1

PTO/SB/09B (10-01)

Approved for use through 10/31/2002. OMB 0651-0091

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|------------------------|--------------------------|----------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/823,463 |
| | | Filing Date | April 12, 2004 |
| | | First Named Inventor | Schenk, D. B. |
| | | Art Unit | 1647 |
| | | Examiner Name | Nichols, C. J. |
| Sheet 30 of 31 | Attorney Docket Number | 15270J-004754US | |

| | | | |
|----|-----|--|--|
| Cy | 274 | WEINER et al., "Nasal administration of amyloid- β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease," <u>Annals of Neurology</u> , 48:567-579 (2000). | |
| | 171 | WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," <u>Annu. Rev. Immunol.</u> , 12:809-837 (1994). | |
| | 172 | WEISSMANN et al., "Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease," <u>Curr. Opin. Neurobiol.</u> , 7:695-700 (1997). | |
| | 387 | WELDON et al., "Neurotoxicity of A β Peptide: Confocal Imaging of Cellular Changes Induced by - Amyloid in Rat CNS <i>In Vivo</i> ," <u>Society for Neuroscience Abstracts</u> , 22(Part 1) (1996). | |
| | 429 | WELLS, J. A., "Additivity of Mutational Effects in Proteins," <u>Biochemistry</u> , 29(37):8608-8617 (1990). | |
| | 180 | WEN, G.Y., "Alzheimer's Disease and Risk Factors," <u>J. Food Drug Analysis</u> , 6(2):465-476 (1998). | |
| | 170 | WENGENACK et al., "Targeting Alzheimer amyloid plaques <i>in vivo</i> ," <u>Nature Biotech.</u> , 18:868-872 (2000). | |
| | 474 | WINTER et al., "Humanized antibodies" <u>Immunology Today</u> , 14(6):243-246 (1998). | |
| | 223 | WISCONSIN ALUMNI RESEARCH FOUNDATION, "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals", U.S. Govt. Res. Develop. Rep., 70(24), 58. (Publication date unknown.) | |
| | 468 | WISNIEWSKI et al., "Alzheimer's disease and soluble A beta," <u>Neurobiol. Aging</u> , 15(2):143-52 (1994). | |
| | 385 | WISNIEWSKI et al., "Therapeutics in Alzheimer's and Prion Diseases," <u>Biochemical Society Transactions</u> , 30(4):574-587 (2002). | |
| | 219 | WONG et al., "Neuritic Plaques and Cerebrovascular Amyloid in Alzheimer Disease are Antigenically Related," <u>PNAS</u> , 82:8729-8732 (1985). | |
| | 173 | WOOD et al., "Amyloid precursor protein processing and A β 42 deposition in a transgenic mouse model of Alzheimer disease," <u>PNAS</u> , 94: 1860-1866 (1997). | |
| | 506 | WOOD et al., "Prolines and amyloidogenicity in fragments of the Alzheimer's peptide β A4" <u>Biochemistry</u> , 34:724-730 (1995). | |
| Cy | 275 | WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier <i>in vivo</i> with a monoclonal antibody to the human insulin receptor," <u>J. Clin. Invest.</u> , 100:1804-1812 (1997). | |

| | | | |
|--------------------|--|-----------------|------------|
| Examiner Signature | | Date Considered | 09/10/2005 |
|--------------------|--|-----------------|------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60475801 v1

PTO/SB/05B (10-01)

Approved for use through 10/31/2002. CMB 0551-0001

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|----|--------------------------|-----------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/823,463 |
| | | Filing Date | April 12, 2004 |
| | | First Named Inventor | Schenk, D. B. |
| | | Art Unit | 1847 |
| | | Examiner Name | Nichols, C. J. |
| | | Attorney Docket Number | 15270J-004754US |
| Sheet | 31 | of | 31 |

| | | | |
|-----|-----|---|--|
| cym | 567 | WU et al., "An Analysis of the Sequences of the Variable Regions of Bence Jones Proteins and Myeloma Light Chains and their Implications for Antibody Complementarity," <u>J. Exp. Med.</u> , 132:211-250 (1970). | |
| | 507 | XU et al., "Increased incidence of anti- β -amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease," <u>Mechanisms of Ageing and Development</u> , 94:213-222 (1997). | |
| | 282 | YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," <u>Acta Neuropathol.</u> , 95:217-222 (1998). | |
| | 430 | YANG et al., "Effects of Racemization on the Aggregational Properties of the Amyloid β -Peptide in Alzheimer's Disease," abstract # 255 from American Chemical Society 214th National Meeting (1997). | |
| | 290 | YOUNGIN, "Amyloid β vaccination: reduced plaques and improved cognition," <u>Nature Medicine</u> , 7:18-19 (2001). | |
| | 483 | ZLOKOVIC et al., "Clearance of amyloid β -peptide from brain: transport or metabolism?," <u>Nature Medicine</u> , 6(7):718-719 (2000). | |
| cym | 580 | ZLOKOVIC et al., "Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers," <u>PNAS</u> , 83(9):4229-4334 (1986) abstract only. | |

| | | | |
|--------------------|----------------------|-----------------|-----------|
| Examiner Signature | <i>Cheng-Yu Wang</i> | Date Considered | 9/15/2005 |
|--------------------|----------------------|-----------------|-----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60475801 v1

| | | | | | |
|--|---|----|---|--------------------------|-----------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete If Known | |
| | | | | Application Number | |
| | | | | Filing Date | |
| | | | | First Named Inventor | |
| | | | | Art Unit | |
| | | | | Examiner Name | |
| Sheet | 1 | of | 1 | Attorney Docket Number | 15270J-004754US |

| U.S. PATENT DOCUMENTS+ | | | | | |
|------------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number Kind Code ² (if known) | | | |
| CW | 440 | 2003/0068316 A1 | 04-10-2003 | Klein et al. | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|--------------------------|---------------------------|---------------------|-----------------------------------|--------------------------------|---|--|--------------------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ^o |
| | | Country Code ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| CW | 441 | WO | 03/104437 | A2 | 12-18-2003 | | | <input type="checkbox"/> |

| | | | |
|-----------------------|---|--------------------|------------|
| Examiner Signature |  | Date Considered | 09/15/2005 |
|-----------------------|---|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.